ES2544805T3 - Exotoxina A de Pseudomonas mejorada con inmunogenicidad reducida - Google Patents
Exotoxina A de Pseudomonas mejorada con inmunogenicidad reducida Download PDFInfo
- Publication number
- ES2544805T3 ES2544805T3 ES10755283.8T ES10755283T ES2544805T3 ES 2544805 T3 ES2544805 T3 ES 2544805T3 ES 10755283 T ES10755283 T ES 10755283T ES 2544805 T3 ES2544805 T3 ES 2544805T3
- Authority
- ES
- Spain
- Prior art keywords
- amino acid
- nucleic acid
- cell
- cytotoxicity
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 title 1
- 230000005847 immunogenicity Effects 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 abstract description 15
- 238000006467 substitution reaction Methods 0.000 abstract description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract description 8
- 235000001014 amino acid Nutrition 0.000 abstract description 8
- 235000004279 alanine Nutrition 0.000 abstract description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract description 5
- 125000000539 amino acid group Chemical group 0.000 abstract description 5
- 239000004471 Glycine Chemical group 0.000 abstract description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Chemical group OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract description 4
- 241000589516 Pseudomonas Species 0.000 abstract description 2
- 101710082714 Exotoxin A Proteins 0.000 abstract 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 19
- 150000007523 nucleic acids Chemical class 0.000 description 18
- 206010028980 Neoplasm Diseases 0.000 description 13
- 230000003013 cytotoxicity Effects 0.000 description 12
- 231100000135 cytotoxicity Toxicity 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 11
- 102000039446 nucleic acids Human genes 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 230000001472 cytotoxic effect Effects 0.000 description 7
- 229940051026 immunotoxin Drugs 0.000 description 7
- 239000002596 immunotoxin Substances 0.000 description 7
- 230000002637 immunotoxin Effects 0.000 description 7
- 231100000608 immunotoxin Toxicity 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 231100000433 cytotoxic Toxicity 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000003735 Mesothelin Human genes 0.000 description 4
- 108090000015 Mesothelin Proteins 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical class OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- 101150030083 PE38 gene Proteins 0.000 description 3
- 229940127180 SS1P Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Chemical class OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 2
- 101001070329 Geobacillus stearothermophilus 50S ribosomal protein L18 Proteins 0.000 description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical class OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 238000009739 binding Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002132 lysosomal effect Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229940127171 LMB-2 Drugs 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 101150109894 TGFA gene Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 208000024340 acute graft versus host disease Diseases 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001294 alanine derivatives Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000001132 aluminium potassium sulphate Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000007514 neuronal growth Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000001194 polyoxyethylene (40) stearate Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24162009P | 2009-09-11 | 2009-09-11 | |
| US241620P | 2009-09-11 | ||
| PCT/US2010/048504 WO2011032022A1 (en) | 2009-09-11 | 2010-09-10 | Improved pseudomonas exotoxin a with reduced immunogenicity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2544805T3 true ES2544805T3 (es) | 2015-09-04 |
Family
ID=43446435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10755283.8T Active ES2544805T3 (es) | 2009-09-11 | 2010-09-10 | Exotoxina A de Pseudomonas mejorada con inmunogenicidad reducida |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8936792B2 (enExample) |
| EP (1) | EP2475398B1 (enExample) |
| JP (1) | JP5795765B2 (enExample) |
| CN (1) | CN102655882B (enExample) |
| AU (1) | AU2010292069B2 (enExample) |
| CA (1) | CA2773665C (enExample) |
| ES (1) | ES2544805T3 (enExample) |
| RU (1) | RU2012114005A (enExample) |
| WO (1) | WO2011032022A1 (enExample) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2332970B1 (en) * | 2005-07-29 | 2015-12-23 | The Government of the United States of America, as represented by the Secretary of Health and Human Services | Mutated pseudomonas exotoxins with reduced antigenicity |
| US9623117B2 (en) * | 2011-04-04 | 2017-04-18 | Wisconsin Alumni Research Foundation | Method for selective targeting and entry of bacterial toxins to cells |
| EP2998320B1 (en) | 2011-04-19 | 2018-07-18 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Human monoclonal antibodies specific for glypican-3 and use thereof |
| CA2835070C (en) * | 2011-05-06 | 2021-07-06 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Recombinant immunotoxin targeting mesothelin |
| KR20140033391A (ko) * | 2011-06-09 | 2014-03-18 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 면역원성이 보다 낮은 t 세포 및/또는 b 세포 에피토프를 갖는 슈도모나스 외독소 a |
| US8932586B2 (en) | 2011-09-06 | 2015-01-13 | Intrexon Corporation | Modified forms of Pseudomonas exotoxin A |
| WO2013039916A1 (en) | 2011-09-12 | 2013-03-21 | The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services | Compositions for and methods of treatment and enhanced detection of non-pituitary tumors |
| HK1198170A1 (en) | 2011-09-16 | 2015-03-13 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Pseudomonas exotoxin a with less immunogenic b cell epitopes |
| WO2013059593A1 (en) | 2011-10-20 | 2013-04-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd22 chimeric antigen receptors |
| KR102159773B1 (ko) | 2012-06-01 | 2020-09-28 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 글리피칸-3에 대한 고친화력 단클론 항체 및 이의 용도 |
| EP2869837B1 (en) | 2012-07-04 | 2016-09-14 | F. Hoffmann-La Roche AG | Anti-theophylline antibodies and methods of use |
| KR102090849B1 (ko) | 2012-07-04 | 2020-03-19 | 에프. 호프만-라 로슈 아게 | 공유 결합된 항원-항체 접합체 |
| EP3339328A1 (en) | 2012-07-04 | 2018-06-27 | F. Hoffmann-La Roche AG | Anti-biotin antibodies and methods of use |
| CA2882753C (en) | 2012-08-21 | 2021-08-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mesothelin domain-specific monoclonal antibodies and use thereof |
| AU2013324049B2 (en) | 2012-09-27 | 2017-09-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mesothelin antibodies and methods for eliciting potent antitumor activity |
| US9725512B2 (en) | 2012-11-08 | 2017-08-08 | Hoffmann-La Roche Inc. | HER3 antibodies binding to the beta-hairpin of HER3 |
| JP6553515B2 (ja) * | 2012-12-20 | 2019-07-31 | メディミューン，エルエルシー | 免疫複合体の製造方法 |
| WO2014205187A1 (en) | 2013-06-20 | 2014-12-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cytolethal distending toxin subunit b conjugated or fused to bacillus anthracis toxin lethal factor |
| CN105849120A (zh) * | 2013-10-06 | 2016-08-10 | 美国卫生和人力服务部 | 修饰的假单胞菌外毒素a |
| US9765142B2 (en) | 2013-10-11 | 2017-09-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | TEM8 antibodies and their use in treatment and detection of tumors |
| US20160280798A1 (en) | 2013-11-06 | 2016-09-29 | The United States Of America, As Represented By The Secretary Department Of Health & Human Service | Alk antibodies, conjugates, and chimeric antigen receptors, and their use |
| CA2932958A1 (en) | 2013-12-20 | 2015-06-25 | F. Hoffmann-La Roche Ag | Humanized anti-tau(ps422) antibodies and methods of use |
| PL3089996T3 (pl) | 2014-01-03 | 2021-12-13 | F. Hoffmann-La Roche Ag | Dwuswoiste przeciwciała przeciw haptenowi/przeciw receptorowi występującemu w barierze krew-mózg, ich kompleksy i ich zastosowanie jako przenośniki wahadłowe występujące w barierze krew-mózg |
| JP6602304B2 (ja) | 2014-01-03 | 2019-11-06 | エフ．ホフマン−ラ ロシュ アーゲー | 共有結合で連結されたヘリカー−抗ヘリカー抗体コンジュゲートおよびその用途 |
| EP3089759B1 (en) | 2014-01-03 | 2018-12-05 | F. Hoffmann-La Roche AG | Covalently linked polypeptide toxin-antibody conjugates |
| US10421958B2 (en) | 2014-02-05 | 2019-09-24 | Molecular Templates, Inc. | Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity |
| AR100978A1 (es) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS |
| EP3473271B1 (en) | 2014-07-31 | 2022-07-20 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Human monoclonal antibodies against epha4 and their use |
| WO2016146833A1 (en) | 2015-03-19 | 2016-09-22 | F. Hoffmann-La Roche Ag | Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance |
| ES2809728T3 (es) | 2015-06-24 | 2021-03-05 | Hoffmann La Roche | Anticuerpos anti-tau(pS422) humanizados y procedimientos de uso |
| WO2017049296A1 (en) | 2015-09-20 | 2017-03-23 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Monoclonal antibodies specific for fibroblast growth factor receptor 4 (fgfr4) and methods of their use |
| CN106589131B (zh) * | 2015-10-19 | 2021-06-11 | 山东省妇幼保健院 | 融合蛋白4D5Fv-PE25及其制备方法和用途 |
| EP3184547A1 (en) | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
| US10925969B2 (en) | 2015-11-13 | 2021-02-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Service | Anti-BCMA polypeptides and proteins |
| WO2017196847A1 (en) | 2016-05-10 | 2017-11-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens |
| WO2017214182A1 (en) | 2016-06-07 | 2017-12-14 | The United States Of America. As Represented By The Secretary, Department Of Health & Human Services | Fully human antibody targeting pdi for cancer immunotherapy |
| AU2017305170A1 (en) | 2016-08-02 | 2019-02-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof |
| WO2018119279A1 (en) | 2016-12-21 | 2018-06-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies specific for flt3 and uses thereof |
| WO2018213612A1 (en) | 2017-05-18 | 2018-11-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin polypeptides and proteins |
| WO2018213064A1 (en) | 2017-05-19 | 2018-11-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibody targeting tnfer2 for cancer immunotherapy |
| WO2019005208A1 (en) | 2017-06-30 | 2019-01-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY |
| WO2019006280A1 (en) | 2017-06-30 | 2019-01-03 | Lentigen Technology, Inc. | HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CD33 AND METHODS OF USE |
| AU2018321825A1 (en) * | 2017-08-19 | 2020-03-05 | Ohio State Innovation Foundation | Novel peptide-based cancer imaging agents |
| WO2019055955A1 (en) | 2017-09-18 | 2019-03-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | IMMUNOTOXINS WITH ALBUMIN BINDING DOMAIN |
| EP3820903A1 (en) | 2018-07-12 | 2021-05-19 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Affinity matured cd22-specific monoclonal antibody and uses thereof |
| WO2020033430A1 (en) | 2018-08-08 | 2020-02-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | High affinity monoclonal antibodies targeting glypican-2 and uses thereof |
| CN109517070A (zh) * | 2018-11-07 | 2019-03-26 | 南京卡提医学科技有限公司 | 嵌合抗原受体DAP12-T2A-CD8α-MSLN scFv-TREM1及其用途 |
| EP3883608A1 (en) | 2019-01-08 | 2021-09-29 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Cross-species single domain antibodies targeting mesothelin for treating solid tumors |
| AU2020212534A1 (en) | 2019-01-22 | 2021-07-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | High affinity monoclonal antibodies targeting glypican-1 and methods of use |
| EP3994173A1 (en) | 2019-07-02 | 2022-05-11 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Monoclonal antibodies that bind egfrviii and their use |
| CN114729041B (zh) | 2019-10-22 | 2024-12-31 | 美国政府(由卫生和人类服务部的部长所代表) | 用于治疗多种实体瘤的靶向b7h3（cd276）的高亲和力纳米抗体 |
| WO2021097289A1 (en) | 2019-11-15 | 2021-05-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Pegylated recombinant immunotoxins |
| WO2022093745A1 (en) | 2020-10-26 | 2022-05-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting sars coronavirus spike protein and uses thereof |
| CA3199368A1 (en) | 2020-11-18 | 2022-05-27 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Tyrosyl-lock peptides |
| US20240075158A1 (en) | 2020-12-22 | 2024-03-07 | Jiangsu Hengrui Pharmaceutical Co., Ltd. | Complex of anti-il-4r antibody or antigen-binding fragment thereof and medical use thereof |
| US20240218055A1 (en) | 2021-04-29 | 2024-07-04 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Lassa virus-specific nanobodies and methods of their use |
| US20240270851A1 (en) | 2021-06-09 | 2024-08-15 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Cross species single domain antibodies targeting pd-l1 for treating solid tumors |
| WO2023076881A1 (en) | 2021-10-26 | 2023-05-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein |
| US20250018040A1 (en) | 2021-12-17 | 2025-01-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Anti-mesothelin polypeptides, proteins, and chimeric antigen receptors |
| WO2024050399A1 (en) | 2022-09-01 | 2024-03-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes |
| WO2024238346A1 (en) | 2023-05-12 | 2024-11-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies that specifically bind the s2 subunit of sars-cov-2 spike protein and compositions and uses thereof |
| WO2025014896A1 (en) | 2023-07-07 | 2025-01-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Humanized 40h3 antibody |
| WO2025019228A1 (en) | 2023-07-20 | 2025-01-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors |
| WO2025106427A1 (en) | 2023-11-14 | 2025-05-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing and protective monoclonal antibodies against respiratory syncytial virus (rsv) |
| WO2025171238A1 (en) | 2024-02-07 | 2025-08-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that bind the juxta-membrane region of mesothelin and uses thereof |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| WO1987002671A1 (en) | 1985-11-01 | 1987-05-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4892827A (en) | 1986-09-24 | 1990-01-09 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5242824A (en) | 1988-12-22 | 1993-09-07 | Oncogen | Monoclonal antibody to human carcinomas |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5055303A (en) | 1989-01-31 | 1991-10-08 | Kv Pharmaceutical Company | Solid controlled release bioadherent emulsions |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
| US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| AU646673B2 (en) | 1990-05-11 | 1994-03-03 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Improved pseudomonas exotoxins of low animal toxicity and high cytocidal activity |
| US5846535A (en) | 1990-10-12 | 1998-12-08 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for reducing tumor cell growth by using antibodies with broad tumor reactivity and limited normal tissue reactivity |
| US5889157A (en) | 1990-10-12 | 1999-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Humanized B3 antibody fragments, fusion proteins, and uses thereof |
| US5608039A (en) | 1990-10-12 | 1997-03-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Single chain B3 antibody fusion proteins and their uses |
| US5981726A (en) | 1990-10-12 | 1999-11-09 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric and mutationally stabilized tumor-specific B1, B3 and B5 antibody fragments; immunotoxic fusion proteins; and uses thereof |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| AU668384B2 (en) | 1992-03-12 | 1996-05-02 | Alkermes Controlled Therapeutics, Inc. | Controlled release ACTH containing microspheres |
| ATE314475T1 (de) | 1992-06-18 | 2006-01-15 | Us Gov Health & Human Serv | Rekombinantes pseudomonas exotoxin mit gesteigerter aktivität |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| US5747654A (en) | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
| US5686578A (en) | 1994-08-05 | 1997-11-11 | Immunomedics, Inc. | Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype |
| US5888773A (en) | 1994-08-17 | 1999-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Method of producing single-chain Fv molecules |
| US6518061B1 (en) | 1995-03-15 | 2003-02-11 | The United States Of America As Represented By The Department Of Health And Human Services | IL-13 receptor specific chimeric proteins and uses thereof |
| CA2241604C (en) | 1996-01-05 | 2010-03-30 | Ira Pastan | Mesothelium antigen and methods and kits for targeting it |
| JP2002501488A (ja) | 1997-03-20 | 2002-01-15 | アメリカ合衆国 | Ｃｄ２２を保有する細胞および腫瘍へ標的化された、組換え抗体および免疫複合体 |
| AU7071598A (en) | 1997-04-10 | 1998-10-30 | Erasmus University Rotterdam | Diagnosis method and reagents |
| US6809184B1 (en) | 1997-12-01 | 2004-10-26 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use |
| US6296843B1 (en) | 1998-04-03 | 2001-10-02 | The Penn State Research Foundation | Mutagenized IL 13-based chimeric molecules |
| CA2374398C (en) | 1999-05-27 | 2011-03-15 | Ira Pastan | Immunoconjugates having high binding affinity |
| AU1599301A (en) | 1999-11-11 | 2001-06-06 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Modulating IL-13 activity using mutated IL-13 molecules that are antagonists or agonists of IL-13 |
| WO2002040545A2 (en) | 2000-11-17 | 2002-05-23 | The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services | Reduction of the nonspecific animal toxicity of immunotoxins by mutating the framework regions of the fv to lower the isoelectric point |
| ES2342929T3 (es) | 2001-09-26 | 2010-07-19 | The Government of the United States of America as represented by the Secretary of Health and Human | Anticuerpos anti-cd22 con afinidad aumentada por las celulas leucemicas que expresan cd22. |
| JP2005508375A (ja) | 2001-11-09 | 2005-03-31 | ネオファーム、インコーポレイティッド | Ｉｌ−１３を発現する腫瘍の選択的治療 |
| AU2003239248A1 (en) | 2002-06-07 | 2003-12-22 | The Government Of The United States, As Represented By The Secretary Of The Department Of Health And | Anti-cd30 stalk and anti-cd30 antibodies suitable for use in immunotoxins |
| AU2004293471C1 (en) | 2003-11-25 | 2011-02-24 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services | Mutated anti-CD22 antibodies and immunoconjugates |
| EP2332970B1 (en) | 2005-07-29 | 2015-12-23 | The Government of the United States of America, as represented by the Secretary of Health and Human Services | Mutated pseudomonas exotoxins with reduced antigenicity |
| PT2197903E (pt) * | 2007-09-04 | 2015-01-02 | Us Gov Health & Human Serv | Delecções no domínio ii da exotoxina a de pseudomonas que reduzem toxicidade não específica |
-
2010
- 2010-09-10 WO PCT/US2010/048504 patent/WO2011032022A1/en not_active Ceased
- 2010-09-10 AU AU2010292069A patent/AU2010292069B2/en active Active
- 2010-09-10 ES ES10755283.8T patent/ES2544805T3/es active Active
- 2010-09-10 US US13/395,422 patent/US8936792B2/en active Active
- 2010-09-10 EP EP20100755283 patent/EP2475398B1/en active Active
- 2010-09-10 JP JP2012528940A patent/JP5795765B2/ja not_active Expired - Fee Related
- 2010-09-10 CN CN201080049559.3A patent/CN102655882B/zh not_active Expired - Fee Related
- 2010-09-10 CA CA2773665A patent/CA2773665C/en active Active
- 2010-09-10 RU RU2012114005/10A patent/RU2012114005A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2475398A1 (en) | 2012-07-18 |
| US8936792B2 (en) | 2015-01-20 |
| CN102655882B (zh) | 2014-11-19 |
| CA2773665C (en) | 2018-02-20 |
| JP5795765B2 (ja) | 2015-10-14 |
| CA2773665A1 (en) | 2011-03-17 |
| EP2475398B1 (en) | 2015-05-20 |
| WO2011032022A1 (en) | 2011-03-17 |
| JP2013504328A (ja) | 2013-02-07 |
| CN102655882A (zh) | 2012-09-05 |
| US20120263674A1 (en) | 2012-10-18 |
| AU2010292069A1 (en) | 2012-04-05 |
| RU2012114005A (ru) | 2013-10-20 |
| AU2010292069B2 (en) | 2015-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2544805T3 (es) | Exotoxina A de Pseudomonas mejorada con inmunogenicidad reducida | |
| ES2525488T3 (es) | Deleciones en el dominio II de la exotoxina A de pseudomonas que reducen la toxicidad inespecífica | |
| ES2659039T3 (es) | Exotoxinas de pseudomonas mutadas con antigenicidad reducida | |
| CN103648525B (zh) | 靶向间皮素的重组免疫毒素 | |
| FitzGerald et al. | Recombinant immunotoxins for treating cancer | |
| CN108840923B (zh) | 一种靶向pd-l1的多肽及其应用 | |
| Hashimoto et al. | Roles of the first-generation claudin binder, Clostridium perfringens enterotoxin, in the diagnosis and claudin-targeted treatment of epithelium-derived cancers | |
| US20140341809A1 (en) | High-Affinity DMF5 T Cell Receptor (TCR) Variants | |
| Bera et al. | Comparison of recombinant immunotoxins against LeY antigen expressing tumor cells: influence of affinity, size, and stability | |
| ES2279801T3 (es) | Uso de proteinas de membrana asociadas al cancer de mama (bcpm) para el tratamiento, profilaxis y diagonostico del cancer de mama. | |
| US11208634B2 (en) | Deimmunized therapeutic compositions and methods | |
| US8901070B2 (en) | Pharmaceutical compositions comprising pore-forming proaerolysin protein (PRX302) | |
| EP4490298A1 (en) | Fusion proteins and uses thereof | |
| CN1966529A (zh) | 含有促性腺激素释放素和绿脓毒素功能片段的重组毒性剂 | |
| HK1263031A1 (en) | Deimmunized therapeutic compositions and methods | |
| HK1179632A (en) | Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity |